The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2018 | OPTIMISMM: benefits of a new triplet therapy for MM patients relapsing on lenalidomide
Meletios Dimopoulos, MD, of the University of Athens School of Medicine, Athens, Greece, gives an overview of the OPTIMISMM trial (NCT01734928) at the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX. This trial compared progression free survival (PFS) of dexamethasone/bortezomib and a triplet of dexamethasone, bortezomib and pomalidomide in patients with multiple myeloma (MM) that have previously been treated with lenalidomide. The positive PFS data from the triplet regimen, even in patients who have acquired resistance to lenalidomide, suggests a positivbe future for this therapy.
